This situation has my attention. The smaller player seems likely to come out on top. I'll observe the big competitors battling it out, aware that my cash won't go to either side.
Novo Nordisk sues Eli Lilly for false advertising
Summary
Will Novo win its false advertising suit against Lilly and how does high-dose semaglutide compare to tirzepatide?
Forum users expect the case to settle without a trial. They note that 7.2 mg semaglutide produced only modestly better weight loss than 2.4 mg while causing substantially more GI side effects. Most participants view tirzepatide as the stronger drug on both efficacy and tolerability, which undercuts Novo’s position in court.
What this discussion establishes- High-dose sema reached 18.7 % weight loss versus 15.6 % at standard dose but with 70 % GI events
- Tirzepatide still outperformed even the highest sema doses tested
- Participants predict a quick settlement that adds minor label language
- Side-effect burden at 7.2 mg described as severe by multiple users
- Lawsuit seen mainly as marketing theater in a market projected over $100 billion
Whether Novo has any realistic chance of prevailing or if the suit is simply a publicity move.
Nothing here is advice.
13 replies · 11 people
↳ replying to @AmberCinder46
Yeah, the lower amount already triggered some nasty reactions for me with sema. No interest in finding out how much rougher things get once the dose goes up.
↳ replying to @PlainCompass54
Maybe the folks in those trials mostly wondered if life was still worth sticking around for as the weight came off.
In that research the bigger amount of the first medication produced a reduction of eighteen point seven percent compared with fifteen point six for the smaller dose. Both stayed below the twenty percent mark reached by the rival product. Raising the dose brought only a modest gain in results for the original drug while more than seventy percent dealt with digestive problems. Tingling sensations rose almost fourfold and close to seven percent ran into major complications. I cannot see the reason for pushing this into lawsuits when the other option looks stronger at dropping weight and triggers fewer reactions.
↳ replying to @SteadySignal69
The huge future value of the domestic market for weight loss treatments is what fuels their intense rivalry. Leading firms are struggling hard to take control there, based on forecasts of major growth ahead. That leaves plenty of room to consider in other countries as well.
Attorneys are probably jumping for joy at the earnings they'll receive.
↳ replying to @SteadySignal69
Appreciate the fixes on several of those irritating central spots in the write-up.
↳ replying to @PlainCompass54
7.2 mg??... Oh god... 🤯🤯
Everyone agrees this option ranks last for shedding pounds among typical users and brings extra drawbacks when matched against the other choice. There's no chance the maker comes out ahead.
↳ replying to @GreyAlder39
Goodness I have no idea why but this amuses me greatly. Yikes though that high dose of the med? Naturally folks shed pounds since they're dealing with nonstop toilet trips or doubled over in pain unable to reach food. Ha. Lawyers will end up wealthy from the upcoming legal fights. Feels good to stay in the unregulated area and just watch the drama unfold.
Just thinking about the bigger amounts tested in those trials still turns my stomach, since I've already put up with queasiness for a whole year on a tiny dose of this one. The maker is falling behind because the rival version works better while causing fewer issues at once, and even its top level beats the largest amounts they tried for theirs in the follow-up test. The unwanted effect numbers from the bigger dose research also looked rough.
I can't picture this matter reaching a courtroom at all. A settlement will happen instead, the maker will slip in one extra sentence on their ad, and everything ends there. This legal action turns out to promote the stronger formula that works better even though it carries more drawbacks.
Add your experience
If you have tried it, this topic is still open. Sign in to reply — it takes a minute.